These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16553578)

  • 1. Losartan: lessons learned from the RENAAL study.
    Shahinfar S; Lyle PA; Zhang Z; Keane WF; Brenner BM
    Expert Opin Pharmacother; 2006 Apr; 7(5):623-30. PubMed ID: 16553578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study.
    Shahinfar S; Dickson TZ; Ahmed T; Zhang Z; Ramjit D; Smith RD; Brenner BM;
    Kidney Int Suppl; 2002 Dec; (82):S64-7. PubMed ID: 12410858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union.
    Gerth WC; Remuzzi G; Viberti G; Hannedouche T; Martinez-Castelao A; Shahinfar S; Carides GW; Brenner B
    Kidney Int Suppl; 2002 Dec; (82):S68-72. PubMed ID: 12410859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Losartan and end-organ protection--lessons from the RENAAL study.
    Kowey PR; Dickson TZ; Zhang Z; Shahinfar S; Brenner BM;
    Clin Cardiol; 2005 Mar; 28(3):136-42. PubMed ID: 15813620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study.
    Kurokawa K; Chan JC; Cooper ME; Keane WF; Shahinfar S; Zhang Z
    Clin Exp Nephrol; 2006 Sep; 10(3):193-200. PubMed ID: 17009077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
    Carr AA; Kowey PR; Devereux RB; Brenner BM; Dahlöf B; Ibsen H; Lindholm LH; Lyle PA; Snapinn SM; Zhang Z; Edelman JM; Shahinfar S
    Am J Cardiol; 2005 Dec; 96(11):1530-6. PubMed ID: 16310435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
    Keane WF; Lyle PA;
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S22-5. PubMed ID: 12612946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Losartan in diabetic nephropathy.
    Perico N; Ruggenenti P; Remuzzi G
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT.
    Riphagen IJ; Deetman PE; Bakker SJ; Navis G; Cooper ME; Lewis JB; de Zeeuw D; Lambers Heerspink HJ
    Diabetes; 2014 Aug; 63(8):2845-53. PubMed ID: 24677717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.
    Zhang Z; Shahinfar S; Keane WF; Ramjit D; Dickson TZ; Gleim GW; Mogensen CE; de Zeeuw D; Brenner BM; Snapinn SM
    J Am Soc Nephrol; 2005 Jun; 16(6):1775-80. PubMed ID: 15872078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial).
    Schutte E; Lambers Heerspink HJ; Lutgers HL; Bakker SJ; Vart P; Wolffenbuttel BH; Umanath K; Lewis JB; de Zeeuw D; Gansevoort RT
    Am J Kidney Dis; 2015 Sep; 66(3):450-8. PubMed ID: 25987260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
    Bakris GL; Weir MR; Shanifar S; Zhang Z; Douglas J; van Dijk DJ; Brenner BM;
    Arch Intern Med; 2003 Jul; 163(13):1555-65. PubMed ID: 12860578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
    de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
    Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Japanese subpopulation analysis of the RENAAL, the landmark trial, is welcomed by our society.
    Kimura G
    Clin Exp Nephrol; 2006 Sep; 10(3):226-7. PubMed ID: 17009082
    [No Abstract]   [Full Text] [Related]  

  • 15. The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland--an analysis of the RENAAL study.
    Szucs TD; Sandoz MS; Keusch GW
    Swiss Med Wkly; 2004 Aug; 134(31-32):440-7. PubMed ID: 15389347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Economic impact of Losartan use in type 2 diabetic patients with nephropathy].
    González F F; Fuentes C V; Castro H C; Santelices L JP; Lorca H E
    Rev Med Chil; 2009 May; 137(5):634-40. PubMed ID: 19701552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
    Miao Y; Dobre D; Heerspink HJ; Brenner BM; Cooper ME; Parving HH; Shahinfar S; Grobbee D; de Zeeuw D
    Diabetologia; 2011 Jan; 54(1):44-50. PubMed ID: 20882268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study.
    Tershakovec AM; Keane WF; Zhang Z; Lyle PA; Appel GB; McGill JB; Parving HH; Cooper ME; Shahinfar S; Brenner BM
    Diabetes Care; 2008 Mar; 31(3):445-7. PubMed ID: 18070995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT).
    Lambers Heerspink HJ; Weldegiorgis M; Inker LA; Gansevoort R; Parving HH; Dwyer JP; Mondal H; Coresh J; Greene T; Levey AS; de Zeeuw D
    Am J Kidney Dis; 2014 Feb; 63(2):244-50. PubMed ID: 24210590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study.
    Chan JC; Wat NM; So WY; Lam KS; Chua CT; Wong KS; Morad Z; Dickson TZ; Hille D; Zhang Z; Cooper ME; Shahinfar S; Brenner BM; Kurokawa K;
    Diabetes Care; 2004 Apr; 27(4):874-9. PubMed ID: 15047641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.